Improving Mathematical Models of Cancer through Game-Theoretic Modelling: A Study in Non-Small Cell Lung Cancer

We examined a dataset of 590 Non-Small Cell Lung Cancer patients treated with either chemotherapy or immunotherapy using a game-theoretic model that includes both the evolution of therapy resistance and a cost of resistance. We tested whether the game-theoretic model provides a better fit than classical mathematical models of population growth (exponential, logistic, classic Bertalanffy, general Bertalanffy, Gompertz, general Gompertz). To our knowledge, this is the first time a large clinical patient cohort (as opposed to only in-vitro data) has been used to apply a game-theoretic cancer model. The game-theoretic model provided a better fit to the tumor dynamics of the 590 Non-Small Cell Lung Cancer patients than any of the non-evolutionary population growth models. This was not simply due to having more parameters in the game-theoretic model. The game-theoretic model was seemingly able to fit more accurately patients whose tumor burden exhibit a U-shaped trajectory over time. We explained how this game-theoretic model provides predictions of future tumor growth based on just a few initial measurements. Using the estimates for treatment-specific parameters, we then explored alternative treatment protocols and their expected impact on tumor growth and patient outcome. As such, the model could possibly be used to suggest patient-specific optimal treatment regimens with the goal of minimizing final tumor burden. Therapeutic protocols based on game-theoretic modeling can help to predict tumor growth, and could potentially improve patient outcome in the future. The model invites evolutionary therapies that anticipate and steer the evolution of therapy resistance.

[1]  M. Guckenberger,et al.  Quality-of-life and toxicity in cancer patients treated with multiple courses of radiation therapy , 2022, Clinical and translational radiation oncology.

[2]  Jakob Nikolas Kather,et al.  Can the Kuznetsov Model Replicate and Predict Cancer Growth in Humans? , 2022, bioRxiv.

[3]  Jakob Nikolas Kather,et al.  Classical mathematical models for prediction of response to chemotherapy and immunotherapy , 2021, bioRxiv.

[4]  Joel s. Brown,et al.  Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One? , 2021, Frontiers in Immunology.

[5]  Joel s. Brown,et al.  Evolutionary Dynamics of Treatment-Induced Resistance in Cancer Informs Understanding of Rapid Evolution in Natural Systems , 2021, Frontiers in Ecology and Evolution.

[6]  R. Gatenby,et al.  Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics , 2021, Neoplasia.

[7]  J. Tepper,et al.  Radiation therapy‐associated toxicity: Etiology, management, and prevention , 2021, CA: a cancer journal for clinicians.

[8]  M. Althubiti,et al.  Multiple Molecular Mechanisms to Overcome Multidrug Resistance in Cancer by Natural Secondary Metabolites , 2021, Frontiers in Pharmacology.

[9]  Yannick Viossat,et al.  A theoretical analysis of tumour containment , 2021, Nature Ecology & Evolution.

[10]  Joel s. Brown,et al.  Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models , 2021, Cancers.

[11]  Joel s. Brown,et al.  Fisheries management as a Stackelberg Evolutionary Game: Finding an evolutionarily enlightened strategy , 2021, PloS one.

[12]  N. Maitland Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced? , 2021, Cancers.

[13]  Ralf L. M. Peeters,et al.  Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer , 2020, PloS one.

[14]  Joel s. Brown,et al.  The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer , 2020, Dynamic Games and Applications.

[15]  D. Basanta,et al.  Understanding the Evolutionary Games in NSCLC Microenvironment , 2020, bioRxiv.

[16]  P. Maini,et al.  Spatial structure impacts adaptive therapy by shaping intra-tumoral competition , 2020, Communications Medicine.

[17]  J. Ciccolini,et al.  Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective , 2020, Vaccines.

[18]  Wei Huang,et al.  Combination therapy: Future directions of immunotherapy in small cell lung cancer , 2020, Translational oncology.

[19]  N. Raghunand,et al.  Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma , 2020, Journal of clinical medicine.

[20]  Joel s. Brown,et al.  An evolutionary framework for treating pediatric sarcomas , 2020, Cancer.

[21]  Monica Salvioli Game theory for improving medical decisions and managing biological systems , 2020 .

[22]  Robert Gatenby,et al.  Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy , 2020, Cancer Research.

[23]  Li You,et al.  Towards Multidrug Adaptive Therapy , 2020, Cancer Research.

[24]  P. Maini,et al.  The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right. , 2019, Cancer research.

[25]  C. Gridelli,et al.  The role of combination chemo-immunotherapy in advanced non-small cell lung cancer , 2019, Expert review of anticancer therapy.

[26]  D. de Ruysscher,et al.  Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  Robert A. Gatenby,et al.  Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy , 2019, Clinical Cancer Research.

[28]  K. Staňková Resistance games , 2019, Nature Ecology & Evolution.

[29]  Robert A. Gatenby,et al.  Optimizing Cancer Treatment Using Game Theory: A Review , 2019, JAMA oncology.

[30]  Alexander Vladimirsky,et al.  Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory , 2018, bioRxiv.

[31]  Robert A. Gatenby,et al.  Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. , 2018, Journal of theoretical biology.

[32]  Joel s. Brown,et al.  Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer , 2017, Nature Communications.

[33]  J. Boxerman,et al.  Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape , 2017, Journal of Neuro-Oncology.

[34]  David Basanta,et al.  Homeostasis Back and Forth: An Eco-Evolutionary Perspective of Cancer , 2016, bioRxiv.

[35]  David Basanta,et al.  Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer , 2017, Nature Ecology & Evolution.

[36]  J. Issa,et al.  DNA Hypomethylating Drugs in Cancer Therapy. , 2017, Cold Spring Harbor perspectives in medicine.

[37]  Recinda L. Sherman,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival , 2017, Journal of the National Cancer Institute.

[38]  Alexander R A Anderson,et al.  Phase i trials in melanoma: A framework to translate preclinical findings to the clinic. , 2016, European journal of cancer.

[39]  A. Panigrahy,et al.  Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma , 2015, American Journal of Neuroradiology.

[40]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[41]  A. Dalgleish Rationale for combining immunotherapy with chemotherapy. , 2015, Immunotherapy.

[42]  T. Thompson,et al.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches , 2013, Oncogene.

[43]  Paula A. Oliveira,et al.  Estimation of rat mammary tumor volume using caliper and ultrasonography measurements , 2013, Lab Animal.

[44]  Frank Hoebers,et al.  State of the art radiation therapy for lung cancer 2012: a glimpse of the future. , 2013, Clinical lung cancer.

[45]  J. Yager,et al.  Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis , 2013, Steroids.

[46]  Alain Goriely,et al.  A mathematical model of tumor-immune interactions. , 2012, Journal of theoretical biology.

[47]  Joel s. Brown,et al.  Evolutionary dynamics in cancer therapy. , 2011, Molecular pharmaceutics.

[48]  Jan Fagerberg,et al.  Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Gatenby A change of strategy in the war on cancer , 2009, Nature.

[50]  T. Fojo,et al.  The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. , 2007, Clinical breast cancer.

[51]  J. Fletcher Evolutionary Game Theory, Natural Selection, and Darwinian Dynamics , 2006, Journal of Mammalian Evolution.

[52]  W. Schulz,et al.  Causes and consequences of DNA hypomethylation in human cancer. , 2005, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[53]  D L S McElwain,et al.  A history of the study of solid tumour growth: The contribution of mathematical modelling , 2004, Bulletin of mathematical biology.

[54]  T. Vincent,et al.  A G-function approach to fitness minima, fitness maxima, evolutionarily stable strategies and adaptive landscapes , 1999 .

[55]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[56]  S. Fuqua,et al.  Estrogen receptors in resistance to hormone therapy. , 2007, Advances in experimental medicine and biology.

[57]  Aris Persidis,et al.  Cancer multidrug resistance , 1999, Nature Biotechnology.